behavior/neurological
|
• reduced amphetamine-induced motor activity
|
growth/size
|
• reduced body weight after weaning, both males and females
|
homeostasis/metabolism
|
• reduced rectal temperature relative to wild-type
|
|
• increased in the limbic brain areas
• increased levels of the MAO-derived metabolite, DOPAC, relative to COMT-derived metabolite, 3-MT, indicating an impairment of dopamine release
|
muscle
| N |
• no evidence of muscle degeneration
(J:85561)
|
nervous system
| N |
• brain morphology, weight, and size were normal
(J:85561)
|
|
• increased in the limbic brain areas
• increased levels of the MAO-derived metabolite, DOPAC, relative to COMT-derived metabolite, 3-MT, indicating an impairment of dopamine release
|
|
• inhibition of dopamine neurotransmission
• inhibition of glutamate neurotransmission
• normal levels of 5-HT and 5-HIAA in the striatum, limbic system, diencephalon, and brainstem
|
Mouse Models of Human Disease |
OMIM ID | Ref(s) | |
| Parkinson Disease 2, Autosomal Recessive Juvenile; PARK2 | 600116 | J:85561 | |
